NASDAQ · Biotechnology

Dyadic International, Inc. (DYAI) Stock

$1.17 -1.68% NASDAQ: DYAI Healthcare

Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins.

Valuation

MetricValue
Price$1.17
Market Cap$42.63M
P/E Ratio-5.59
P/B Ratio-106.23
P/S Ratio14.58
EPS (TTM)$-0.23
52-Week High$1.60
52-Week Low$0.65
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-700.00%
ROA-93.37%
ROCE-153.31%
Gross Margin-700.00%
Operating Margin-700.00%
Net Margin-245.12%
Debt/Equity-12.39
Current Ratio2.50

Annual Financials (USD)

Metric20212022202320242025
Revenue$2.0M$3.0M$3.0M$3.0M$1.0M
Operating Profit$-15.0M$-10.0M$-8.0M$-6.0M$-7.0M
Net Profit$-13.0M$-10.0M$-7.0M$-6.0M$-7.0M
EPS$-0.47$-0.34$-0.24$-0.20$-0.23
Op Margin-612.7%-346.9%-283.9%-168.8%-579.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$21.0M$14.0M$8.0M$10.0M$10.0M
Total Liabilities$3.0M$3.0M$2.0M$7.0M$9.0M
Cash$16.0M$6.0M$7.0M$7.0M$5.0M
Borrowings$0$0$0$5.0M$5.0M

Latest News

Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program GlobeNewswire · Jul 16, 2026 Dyadic International Progresses Multiple Protein Production Partnerships MT Newswires · Jul 7, 2026 Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential GlobeNewswire · Jul 7, 2026 Dyadic International Receives Japan Patent Allowance for Recombinant Protein Expression Technology MT Newswires · Jun 29, 2026 Dyadic Expands IP Protection and Business Development Activities in Japan GlobeNewswire · Jun 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-11.0M$-8.0M$-7.0M$-4.0M$-6.0M
Investing Cash Flow$5.0M$-2.0M$7.0M$-2.0M$0
Financing Cash Flow$1.0M$1.0M$0$0$0
Net Cash Flow$-5.0M$-10.0M$1.0M$0$-1.0M
Free Cash Flow$-11.0M$-8.0M$-7.0M$-4.0M$-6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.43
EV / EBITDA-6.00
FCF Yield-14.07%
Quick Ratio2.50
Interest Coverage-16.75
Return 1Y22.45%
Return 3Y-35.83%
Return 5Y-64.71%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Dyadic International, Inc.

Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins. Its core activities are underpinned by a patented and proprietary C1 platform, alongside other advanced technologies. This technological foundation drives their research, development, and commercial endeavors, focusing on the creation and manufacturing of various human and animal vaccines and pharmaceutical products. These offerings span a wide range of biological therapeutics, including virus-like particles (VLPs), antigens, monoclonal, bi-specific, and tri-specific antibodies, Fab antibody fragments, Fc-fusion proteins, biosimilars, biobetters, and diverse therapeutic enzymes and proteins. A key pipeline asset is DYAI-100, a SARS-CoV-2-RBD antigen vaccine candidate. This candidate is currently slated for a first-in-human Phase 1 clinical trial, with the objective of establishing proof of concept for the development of next-generation, multivariant COVID-19 vaccine candidates. Dyadic also maintains several strategic alliances, including a research and development agreement with VTT Technical Research Centre of Finland, Ltd., a strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., and a collaboration with Syngene International Limited. Established in 1979, the company is headquartered in Jupiter, Florida.

Dyadic International, Inc. is led by CEO Mark A. Emalfarb, employs 6 people, headquartered in US, publicly traded since 2008.

Dyadic International, Inc. (DYAI) stock trades at $1.17 with a market capitalization of $42.63M. The stock is valued at a price-to-earnings (P/E) ratio of -5.59, price-to-book of -106.23, price-to-sales of 14.58. Over the past 52 weeks the stock has ranged between $0.65 and $1.60, and currently trades 26.9% below its 52-week high.

On profitability, Dyadic International, Inc. generates a return on equity (ROE) of -700.00%, return on capital employed of -153.31%, an operating margin of -700.00%, a net profit margin of -245.12%.

Official website: www.dyadic.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides